

Data Sheet

Product Name: Omadacycline (hydrochloride)


Cat. No.: CS-6352 CAS No.: 1196800-39-1 Molecular Formula: C₂₉H₄₀N₄O₇.HCl

593.11 **Molecular Weight:**

Antibiotic: Bacterial Target: Anti-infection

Solubility: H2O : ≥ 50 mg/mL (84.30 mM); DMSO : 105 mg/mL (177.03

mM; Need ultrasonic)



HCI

BIOLOGICAL ACTIVITY:

Pathway:

Omadacycline (PTK 0796) hydrochloride, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline hydrochloride acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline hydrochloride possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline hydrochloride can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections[1][2][3][4]. IC50 & Target: bacteria^[1] In Vitro: Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae), with MIC₉₀s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively^[2]. Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active

tetracycline efflux^[2]. In Vivo: Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia, Escherichia coli, and Staphylococcus aureus in mice systemic infection model, with ED₅₀s ranging from 0.30 mg/kg to 3.39 mg/kg^[2].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: Omadacycline is dissolved in sterile saline. [1] Mice: Omadacycline is dissolved in sterile saline. Mice are infected using a 3-mL lock-top sterile syringe with a sterile 25-gauge, 5/8-in. needle. At 1 h postinfection (p.i.), mice are dosed intravenously (i.v.) with omadacycline or comparator compounds of interest at a volume of 10 ml/kg. A minimum of four dose levels are tested per experiment with 5 mice/group. The typical doses tested ranges from 0.11 to 18 mg/kg of body weight, with exceptions for comparators that requires significantly higher or lower doses to achieve 50% efficacy^[1].

References:

- [1]. Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35.
- [2]. Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63.
- [3]. Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313.
- [4]. Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937.

Page 1 of 2 www.ChemScene.com

CAIndexNames:

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride, (4S,4aS,5aR,12aS)-

SMILES:

O = C(C1 = C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3 = C(O)C(CNCC(C)(C)C) = CC(N(C)C) = C3C2) = O) = C4O)([H])[C@@]4(O)C1 = O)N.CI(C1 = C(O)[C@@H](N(C)C)[C@@]4(O)C1 = O)N.CI(C1 = C(O)[C@@H](N(C)C)[C@GW](N(C)C)[C@W](N(C)C)[C@W](N(C)C)[C@W](N(C)C)[C@W](N(C)C)[CW](N(C

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com